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Background: Dyspnea and functional limitation in interstitial lung diseases (ILD) are not
always adequately explained by the degree of compromise in pulmonary function alone.
Pulmonary hypertension (PH) is felt to be a major contributor to morbidity and mortality in
these patients. It is not clear whether treatment with newer vaso-active agents benefits
patients with PH in the setting of moderate or severe ILD.
Methods: Medical records of patients followed at our institution between July 2001 and
June 2005 were reviewed to identify patients with moderate or severe fibrotic ILD and PH.
Data regarding demographics, hemodynamics, and clinical characteristics at baseline and
during follow-up were collected.
Results: We identified 19 patients who met our inclusion criteria and in whom vaso-active
therapy [epoprostenol (N ¼ 10), bosentan (N ¼ 9)] was initiated. Most patients [(15/19(79%)]
showed an initial positive response to therapy and improved their 6-min walk distance
(6MWD) by450m (responders) and 12/15 (80%) improved by at least 1 WHO functional class.
At 1-year follow-up, 7 of 15 (47%) ‘responders’ had deteriorated significantly. None of the
patients died during 1 year of follow-up.
Conclusions: Epoprostenol and bosentan produced short-term functional benefit in our
patients with PH and moderate or severe restrictive ILD. The generalizability of these
results awaits the results of larger, prospective, randomized trials in such patients.
& 2008 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
445 2610;
.A. Minai).Introduction
Pulmonary hypertension (PH) refers to elevated pressures in
the pulmonary vasculature. Diffuse parenchymal lung dis-
eases, such as many of the interstitial lung diseases (ILD)1,2
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be complicated by PH. The term ILD refers to a hetero-
geneous group of disorders, many of which have been shown
to be associated with PH. Dyspnea and functional limitation
in ILD are not always adequately explained by the degree of
compromise in pulmonary function alone4–6 and PH is felt to
be a major contributor to the morbidity and mortality in
these patients.4,7 Mechanisms involved in the development
of PH in pulmonary fibrosis are poorly defined but include
vasoconstriction due to hypoxia and/or elevated endothelin-
1 levels,8,9 luminal obliteration, and vascular damage due to
the progressive fibrosis.
Recent publications have shown the short- and long-term
efficacy of various vaso-active agents in the treatment of
patients with pulmonary arterial hypertension (PAH).10
These studies have, however, typically excluded patients
with significant parenchymal lung diseases.11,12 Few data
exist on the utility and efficacy of vasodilator therapy in PH
associated with ILD,13–16 this is especially true of patients
with an associated moderate or severe ventilatory defect.
Attempts at using vasodilators in these patients have been
hampered by various concerns including potential for lack of
efficacy given the fibrotic process and the possibility of
worsening hypoxia.13,16–18 The few reports to date have
focused on acute, short-term responses and, to our knowl-
edge, there are no studies looking at longer term outcomesTable 1 Baseline clinical characteristics of 19 patients with PH
Characteristics N (%)
Age (years) 19
Gender (M/F) 10 (52.6)/9 (4
Underlying disease
IPF 8 (42)
Sarcoidosis 6 (32)
CTDy 5 (26)
WHO class (2/3/4) 0/6 (31.6)/1
6MWD (m) 14z
19y
PFTs 19
FVC (% pred)
FEV1 (% pred) 19
DLCO (% pred) 19
BMI (kg/m2) 19
Patients receiving supplemental oxygen 19
Status at 1 year
Declined transplantation 8
Deemed not a transplant candidate 6
Being evaluated for transplantation 5
BMI: body mass index; BNP: brain natriuretic peptide; DLCO: diffusion
1 s; FVC: forced vital capacity; WHO class: World Health Organizatio
function tests.
IPF (N ¼ 7), fibrotic (UIP pattern) ILD in a patient with rheumato
yScleroderma (N ¼ 4), SLE (N ¼ 1).
zExcluding 5 patients who were in overt right heart failure felt to
yUsing 0m as 6MWD for those in overt right heart failure felt to bein patients with advanced, fibrotic lung disease. We report
our 1-year experience with the compassionate use of vaso-
active agents in a series of patients with moderate or severe
fibrotic ILD and PH.Materials and methods
This report represents the result of a retrospective case series
which was approved by our institutional review board. Medical
records of patients followed in the PH clinic at the Cleveland
Clinic between July 2001 and June 2005 were reviewed to
identify patients with moderate or severe fibrotic ILD and PH.
Patients were included if they had (1) PH; (2) forced vital
capacity o70% on spirometry and fibrosis (not just ground
glass opacification) on a computed tomographic scan of the
chest at the time of initial diagnosis of PH; (3) no evidence of
severe coronary artery disease or left ventricular dysfunction
defined as left ventricular ejection fraction o40%; and (4) at
least one follow-up visit after initiation of vaso-active therapy.
Data regarding demographics, hemodynamics, and clinical
characteristics at baseline and during follow-up were col-
lected. PH at baseline was defined as resting mPAP425mmHg
(N ¼ 16) or trans-thoracic echocardiographic evidence of
right ventricular systolic pressure 460mmHg with right
ventricular dysfunction (N ¼ 3). Initial evaluation for PH wasand fibrotic ILD.
Mean7SD Confidence intervals
56711 51–61
7.4)
3 (68.4)
2547118 186–322
1877152 114–261
49712 43–54.5
47714 40–53
2479 19.5–29
2979 25–33
capacity for carbon monoxide; FEV1: forced expiratory volume in
n functional class; 6MWD: 6-min walk distance; PFT: pulmonary
id arthritis (N ¼ 1).
be too sick to walk at baseline.
too sick to walk at baseline.
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up evaluation and testing were performed at the discretion of
the treating physician.
An initial analysis of the overall group was performed to
evaluate response to therapy over time. A recent case
series14 found a mean improvement of 49m in 6-min walkTable 2 Baseline hemodynamic characteristics of pa-
tients with PH and fibrotic ILD.
Characteristics Mean7SD Confidence intervals
RVSP (mmHg) 79720 68–89
RAPm (mmHg) 1375 10–15
PAPm (mmHg) 49711 43–55
PASP (mmHg) 79717 70–88
CI (ml/min/m2) 270.5 1.7–2.4
PVR 874 6–10.5
SvO2 5879 52–65
CI: cardiac index by Fick method; PASP: pulmonary artery
systolic pressure; PAPm: mean pulmonary arterial pressure;
PVR: pulmonary vascular resistance; RVSP: right ventricular
systolic pressure; RAPm: mean right atrial pressure; SvO2:
mixed venous oxygen saturation.
Table 3 Results of follow-up on vaso-active therapy in respond
No. Etiology Initial
therapy
6MWD
B 3 6 12
Responders (R)
1. IPF Epo 323 491 501 497
2. IPF Bos 148 253 227 TSW
3. IPF Bos 342  454 424
4. IPF Epo 317 372 323 337
5. IPF Bos TSW 219 232 TSW
6. IPF Epo TSW 315 350 280
7. CTD Bos 162 251 288 311
8. CTD Epo 81 85 201 
9. CTD Epo 99 213 323 277
10. CTD Epo 318 387 315 459
11. CTD Epo TSW 191 TSW 
12. Sarcoid Bos 81 162  TSW
13. Sarcoid Bos 238 232 297 273
14. Sarcoid Epo TSW 224 245 TSW
15. Sarcoid Epo TSW 161 212 113
Non-responders (NR)
1. IPF Bos 326 317 TSW TSW
2. IPF Bos 347 352  273
3. Sarcoid Epo 338 303 323 323
4. Sarcoid Bos 440 457 465 459
6MWD: distance walked in 6min; WHO class: World Health Organiz
measured by trans-thoracic echocardiography; IPF: idiopathic pulmon
up; 6: 6 months follow-up; 12: 12 months follow-up; Bos: bosentan; CT
to walk; ND: not done.
Patient not seen at that time point.
yUnable to accurately estimate RVSP by trans-thoracic echocardiodistance (6MWD) in a group of patients with PH and idiopathic
pulmonary fibrosis (IPF) so we divided patients into ‘respon-
ders [R]’ (those with improvement in 6MWD450m at 3 or 6
months follow-up) and ‘non-responders [NR]’ (those with
improvement in 6MWDp50m at 3 and 6 months follow-up).
Subsequently patients were divided into subgroups based on
(1) cause of fibrotic ILD, i.e. connective tissue disease-
related, sarcoidosis, and IPF and (2) severity of restrictive
ventilatory defect, i.e. those with moderate (forced vital
capacity (FVC)X50% to o70%) and severe (FVCo50% pre-
dicted) restriction. Groups were compared with respect to
categorical data using Fisher’s exact test, and with respect to
quantitative data using the Wilcoxon rank sum test.Results
We identified 19 patients followed in our PH clinic who met
our inclusion criteria. Tables 1 and 2 highlight their baseline
clinical (Table 1) and hemodynamic (Table 2) characteristics.
These patients were referred to our clinic for treatment of
PH (N ¼ 12), evaluation of hypoxia or shortness of breath
(N ¼ 4), or evaluation for lung transplantation (N ¼ 3). Vaso-
active therapy was initiated on a compassionate basis and
response to therapy is outlined in Table 3. Although data wasers and non-responders.
WHO class RVSP
B 3 6 12 B 3 6 12
3 2 2 2 91 82 59 57
3 3 3 4 100 86 92 97
3  2 2 64  40 45
4 3 3 3 90 62 62 59
4 3 3 4 99 52 ND 115
4 3 2 3 101 85 56 ND
4 3 3 3 74 81 86 70
4 4 3  89 97 ND 
4 3 3 3 66 81 54 72
3 3 3 2 41 38 47 31
4 4 4  75 81 86 
4 3  4 44 55  ND
4 4 3 3 82 80 ND ND
4 3 3 4 113 75 81 ND
4 3 3 4 73 80 68 80
4 4 4 4 y y y 115
3 2  3 66 60  ND
4 3 3 3 95 89 105 104
3 2 2 2 53 ND ND 36
ation functional class; RVSP: right ventricular systolic pressure
ary fibrosis; Epo: epoprostenol; B: baseline; 3: 3 months follow-
D: connective tissue diseases; sarcoid: sarcoidosis; TSW: too sick
graphy.
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Figure 3 Change in NYHA functional class on therapy in 19
patients with PH and fibrotic ILD at each time point.
O.A. Minai et al.1018collected retrospectively, patients were followed according
to a standardized protocol that included clinical assessment,
6-min walk test (6MWT), and trans-thoracic echocardiogra-
phy before initiation of therapy and every 3 months
thereafter. Five patients did not have a baseline 6MWT
because they were in overt right ventricular failure and were
‘too sick to walk’ in the opinion of the treating clinician.
Most patients [(15/19 (79%)] showed an initial positive
response to therapy and improved their 6MWD by 450m
within the first 6 months (Figures 1 and 2). Patients who had
not responded in the first 6 months remained ‘non-
responders’ at 12 months. Eighty percent of ‘responders’
(12/15) also improved by at least 1 WHO functional class
(Table 3 and Figure 3).
For the purposes of comparing patients with different
underlying diseases and degree of pulmonary function
severity, patients in overt right ventricular failure at
baseline were ascribed a 6MWD of ‘0’m. At 1-year follow-
up, 7 of 15 (47%) ‘responders’ (numbers 2, 5, 8, 11, 12, 14,
and 15) had deteriorated significantly (Table 3 and Figure 2),Figure 1 Time to initial improvement on therapy in 19
patients with PH and fibrotic ILD. Legend: Bars represent the
number of patients improving 6MWD by450m for the first time
at each time point. The curve represents the cumulative
percentage of patients that had improved 6MWD by 450m by
that time point.
Figure 2 Change in 6MWD for ‘responders’ (N ¼ 15) and ‘non-
responders’ (N ¼ 4) on therapy at each time point. Legend:
Data presented as mean (CI); 6-min walk distance is in meters.mostly in the IPF and sarcoid groups. Comparing those with
FVCo50% with those who had FVCX50% (Table 4), there
were no significant differences noted in response to therapy.
None of the patients died during 1 year of follow-up.
Of the patients initiated on epoprostenol as first line
therapy (N ¼ 10) (Table 5), 4 remained on epoprostenol
alone, bosentan was added in 3 patients, 2 were transitioned
to treprostinil because of convenience (IV) or recurrent line
infections (SC), and therapy was discontinued in one patient.
Of the patients initiated on bosentan as first line therapy
(N ¼ 9), 6 remained on bosentan alone and sildenafil was
added in one patient. In 2 other patients bosentan was
discontinued due to ‘lack of clinical benefit’ or worsening. At
1-year follow-up, 4 patients were on combination therapy
and 2 patients were on no vaso-active therapy.Discussion
This is a case series describing the clinical effects of
epoprostenol and bosentan in patients with moderate or
severe ILD and PH. Most of our patients showed an initial
improvement in 6MWD and WHO functional class with the
use of epoprostenol or bosentan. This finding is similar to a
recent report showing initial improvement in 6MWD on
sildenafil in patients with PH and IPF (14). This is an
important finding since the most effective treatment for a
patient with PH and moderate or severe ILD is lung
transplantation. Some of these patients may become
candidates for lung transplantation once they improve their
functional capacity with the use of vaso-active medications
such as epoprostenol, bosentan, or sildenafil.
The longer follow-up in our report demonstrated that
patients who were going to obtain a benefit did so within the
first 6 months of treatment initiation. This suggests that
patients not demonstrating a clinical response by 6 months
into therapy are unlikely to benefit from continued use of
these medications. In fact 47% of initial ‘responders’
demonstrated significant clinical deterioration in their
functional class and 6MWD by 12 months, suggesting that
the window of opportunity for other interventions, such as
lung transplantation, may be relatively small. On the other
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Table 4 Comparison of response to therapy among those with moderate (FVC 50–69% predicted) and severe (FVC o50%
predicted) restrictive lung disease.
Characteristic FVC (%
pred)
Baseline o50%
(N ¼ 11) X50%
(N ¼ 8)
Change at 3
months o50%
(N ¼ 11) X50%
(N ¼ 7)
Change at 6
months o50%
(N ¼ 10) X50%
(N ¼ 7)
Change at 12
months o50%
(N ¼ 9) X50%
(N ¼ 8)
6MWD (m) o50 1647167 1097108 867184 267170
X50 2197134 81.5783 1107101 397117
RVSP (mmHg) o50 80719 8719.5 20722 12722
X50 77723 6.4717 7717 3.5710
WHO class (2/3/4) o50 0/2/9 2/5/4 3/5/2 2/3/4
X50 0/4/4 1/6/0 1/6/0 2/4/2
See legends of Tables 1–3 for abbreviations.
pp0.05 compared to baseline for the same group.
p ¼ 0.08 compared to baseline for the same group.
Table 5 Vaso-active therapy at baseline and 1 year in
patients with PH and fibrotic ILD (N ¼ 19).
Medication Baseline 1 year
Epoprostenol 10 4
Bosentan 9 6
Sildenafil 0 1
Treprostinil 0 2
Epoprostenol and bosentan 0 3
Bosentan and sildenafil 0 1
No therapy 0 2
1 patient on intravenous and 1 on subcutaneous trepros-
tinil.
Vaso-active therapy in patients with pulmonary hypertension 1019hand, this also indicates that treatment with vaso-active
agents should be considered in the management of patients
with ILD and PH since some patients (53% of the initial
‘responders’ in this case) may obtain a more sustained
benefit from their use.
In our overall group of patients, the benefit was less likely
to occur and appeared to be less sustained in patients with
IPF. This occurred despite the fact that patients in the IPF
group had better baseline 6MWD and NYHA functional class
compared to patients with CTD or sarcoidosis. The reasons
for this finding are unclear. There is very little data
regarding the pathogenesis of PH in patients with pulmonary
fibrosis such as IPF. Data suggest that endothelin-1 levels are
elevated in patients with CTD20 and sarcoidosis.21,22 While
some data in patients with IPF points to similarly altered
levels,23,24 other authors have not found this to be the
case.21 We postulate that this may be because patients with
CTDs25,26 and sarcoidosis27 have a primary vaso-constrictive
or vaso-proliferative process in addition to the fibrotic
process, which may be benefited by the use of vaso-active
medications, whereas in patients with advanced IPF the
fibrotic process with obliteration of vessels may take
precedence.The pattern of use of vaso-active therapy at baseline and
1 year reflects the availability of these agents rather than
any perceived difference in efficacy. Many of these patients
were initiated on therapy when epoprostenol and bosentan
were the only vaso-active agents available. Only later, as
other options became available,15 was therapy modified.
In 4 patients (in 2 with bosentan as first line therapy and
in 2 with bosentan use as add-on therapy to epoprostenol),
bosentan was discontinued due to worsening edema, short-
ness of breath, and hypoxia despite diuretic therapy. This
happened over the course of 3–6 months and was likely the
result of increase in vascular volume that can sometimes
occur with bosentan. However, in 2 of these patients,
bosentan was added when it was felt that patients were
deteriorating despite epoprostenol therapy so this may have
been the result of more advanced disease.
This report has the limitations of any retrospective case
series. Results should be interpreted with caution in view of
the small sample size and the lack of a control population.
However, reports such as these can provide valuable
information about current clinical practices and can guide
the design of randomized, controlled trials.
In conclusion, our report shows that most of our patients
with fibrotic ILD received short-term functional benefit from
vaso-active therapy. This benefit was longer lasting in
patients with ILD associated with CTD or sarcoidosis than
in those with fibrosis secondary to IPF. Among our group of
patients, those with more severe pulmonary function
compromise derived more benefit from vaso-active therapy
than patients with less severe pulmonary dysfunction. The
generalizability of these results and the effects of vaso-
active therapy on oxygenation await the results of larger,
prospective, randomized trials in patients with ILD.
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